Back to top
more

MEI Pharma, Inc. (MEIP)

(Delayed Data from NSDQ)

$3.49 USD

3.49
10,757,826

-0.78 (-18.27%)

Updated Jul 2, 2020 04:00 PM ET

Add to portfolio

3-Hold of 5     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.04%
17.51%
9.10%
4.64%
1.64%
10.44%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value F Growth A Momentum F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%

Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

AMPE MEIP

Zacks Equity Research

Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

ZGNX MEIP GWPH AMRX

Zacks Equity Research

Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP

Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP

CALX MEIP YIN OOMA

Nitish Marwah

4 Breakout Stocks for Explosive Returns

The first step to selecting the right breakout stock is to calculate its support and resistance level.

CALX MEIP YIN OOMA

Zacks Equity Research

Go Defensive to Beat Market Turbulence With These 4 Stocks

Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.

ABBV MEIP OLLI VST

Zacks Equity Research

Is the Options Market Predicting a Spike in MEI Pharma (MEIP) Stock?

Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.

MEIP

Kinjel Shah

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.

OCUL NERV MEIP CNCE ATXI

Sanghamitra Saha

Tap the Solid Momentum in These 5 Solid High-Beta Stocks

Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.

EQT ADTN MRNA ETSY MEIP INO

Zacks Equity Research

How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry

MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MEIP

Zacks Equity Research

MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).

MEIP

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for May 15th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 15th

MEIP KOPN IIVI HALO

Zacks Equity Research

The Zacks Analyst Blog Highlights: Ensign, Gaia, MEI Pharma, Turning Point Brands and A10 Networks

The Zacks Analyst Blog Highlights: Ensign, Gaia, MEI Pharma, Turning Point Brands and A10 Networks

GAIA ENSG ATEN MEIP TPB

Nalak Das

5 Top Stocks That Have Skyrocketed in the Past 7 Days

Despite the coronavirus-induced market downturn, a handful of stocks have soared in the last seven trading days defying the overall market trend.

GAIA ENSG ATEN MEIP TPB

Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

DVA RMD ENSG MEIP KALV

Zacks Equity Research

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

DVA RMD ENSG MEIP KALV

Zacks Equity Research

MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%

MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

MEIP IRWD

Zacks Equity Research

Earnings Preview: MEI Pharma (MEIP) Q3 Earnings Expected to Decline

MEI Pharma (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEIP

Zacks Equity Research

MEI Pharma (MEIP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MEI Pharma (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEIP

Zacks Equity Research

MEI Pharma Sees Hammer Chart Pattern: Time to Buy?

MEI Pharma has been struggling lately, but the selling pressure may be coming to an end soon.

MEIP

Zacks Equity Research

Will MEI Pharma (MEIP) Report Negative Earnings Next Week? What You Should Know

MEI Pharma (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEIP

Zacks Equity Research

Implied Volatility Surging for MEI Pharma (MEIP) Stock Options

Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.

MEIP

Zacks Equity Research

Should You Buy MEI Pharma (MEIP) Ahead of Earnings?

MEI Pharma (MEIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MEIP

Zacks Equity Research

Advanced Accelerator (AAAP) in Focus: Stock Moves 10.4% Higher

Advanced Accelerator (AAAP) was a big mover last session, as the company saw its shares more than 10% on the day amid huge volumes.

NVS MEIP AAAP

Zacks Equity Research

Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 10% Higher

Corbus Pharmaceuticals (CRBP) was a big mover last session, as the company saw its shares rise 10% on the day.

MEIP CRBP

Zacks Equity Research

WellCare (WCG) Unit Receives Favorable Star Ratings From CMS

WellCare's (WCG) efforts to boost its Medicare business and provide its Medicare Advantage members quality services have helped it achieve favorable Star Quality ratings from CMS

MEIP HUM